Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc, discusses how payers are planning for biosimilars.
Transcript:
Well, the way payers are going to approach biosimilars depends a little bit on the behavior of the reference product manufacturers.
Let’s say that the reference product manufacturers decide that they don’t really want to compete on price. In which case, I will predict that the commercial payers particularly—and that includes Medicare Advantage—will institute a policy similar to that around the use of generics. That is, they will require the use of the biosimilar first unless there’s a reason you can’t use a biosimilar.
But of course, in today’s world, we have the potential for manufacturers to undercut the price of the biosimilar product by offering a rebate. That is in fact already happening quite extensively in the inflammatory disease space; we will see what happens in the oncology space.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.